MEDIUM confidence: 100% data completeness, but the composite (57) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$1.4M over 180 days (0 open-market buys, 3 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $75 avg across 5 analysts.
Buy-rated share 60% → 70% over ~3 months (+10pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.66 | $0.69 | +4.1% |
| May 2026 | $0.47 | $0.61 | +30.2% |
| Feb 2026 | $0.88 | $0.89 | +1.1% |
| Nov 2025 | $0.53 | $0.59 | +10.7% |
| Aug 2025 | $0.50 | $0.58 | +16.0% |
| May 2025 | $0.35 | $0.41 | +17.1% |
| Feb 2025 | $0.74 | $0.80 | +8.1% |
| Nov 2024 | $0.41 | $0.45 | +9.8% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.1B— | $2.3B+11.3% | $2.4B+5.1% | $2.6B+6.6% | $2.8B+9.2% |
| EPS (dil.) | $1.31— | $1.04-20.6% | $1.40+34.6% | $1.77+26.4% | $2.09+18.1% |
| Free Cash Flow | $234M— | $114M-51.5% | $338M+197.2% | $381M+12.8% | $551M+44.4% |
| Gross Margin | 49.9% | 47.6%-2.3pp | 48.5%+0.9pp | 49.4%+0.8pp | 50.8%+1.4pp |
| Operating Margin | 12.9% | 8.7%-4.2pp | 11.4%+2.6pp | 13.6%+2.2pp | 16.0%+2.4pp |
| Net Margin | 10.6% | 7.5%-3.1pp | 9.6%+2.0pp | 11.4%+1.8pp | 12.2%+0.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 5.4%/yr (revenue basis).
Base free cash flow $423M (avg FY2023–FY2025; latest year $551M) · equity value $11.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The New York Times Company's QScore of 57 indicates a neutral outlook, with the stock's short-term score slightly exceeding its long-term score. The company scores high on risk, with a relatively low beta and moderate volatility, but its value and growth scores are more subdued due to a P/E of 29.0 and revenue growth of 9.2%. Momentum is a bright spot, with a 12-month return of 25.0%, although recent performance has been weaker, with a 3-month decline of 7.1%. Overall, the stock trades at a premium, with a P/B of 5.6, and exhibits strong profitability, with an ROE near 20%.